Protocol Ledger

NCT07614776 · Phase III · RECRUITING

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Interventional Phase III clinical trial protocol NCT07614776 sponsored by Amgen in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-27 Enrollment: 304 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07614776
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)304 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07614776
Protocol FieldVerified Registry Value
NCT IdentifierNCT07614776
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment304 participants (ESTIMATED)
Registered Start Date2026-05-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07614776
Hospital Research SiteLocationSite Profile
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI